Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?

The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on investor priorities—Eli Lilly suits those seeking growth and future dividend increases, while Pfizer appeals to investors prioritizing immediate income.

09/22/2026, 12:02 PM • The Motley Fool

Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities

A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.

09/22/2026, 10:59 AM • GlobeNewswire

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?

The article compares two pharmaceutical dividend stocks: AbbVie and Pfizer. AbbVie is a Dividend King with 50+ consecutive years of dividend increases, offering a 2.6% yield and $18 billion in free cash flow, with strong growth from immunology products like Rinvoq and Skyrizi. Pfizer is in recovery mode post-pandemic, offering a higher 6.2% dividend yield but with less consistent growth. The author recommends AbbVie as the better dividend buy due to its proven ability to grow dividends sustainably and demonstrated business resilience after losing Humira exclusivity.

09/22/2026, 6:05 AM • The Motley Fool

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.

09/20/2026, 8:30 AM • The Motley Fool

3 Dividend Stocks to Buy and Hold for 10 Years

The article recommends three healthcare dividend stocks for long-term investors: Pfizer, Abbott Laboratories, and Medtronic. Despite recent challenges, all three companies offer strong dividend programs with growth potential. Pfizer has a promising pipeline including weight loss and cancer drugs. Abbott benefits from a diversified medical device business and recent acquisitions. Medtronic is positioned for growth through its cardiac ablation solutions and robotic surgery systems.

09/18/2026, 6:13 PM • The Motley Fool

2 High-Yield Dividend Stocks to Buy and 1 to Avoid

The article recommends buying Energy Transfer and Verizon as high-yield dividend stocks, while advising investors to avoid Pfizer. Energy Transfer benefits from AI data center demand for natural gas with a 6.4% yield and strong growth prospects. Verizon offers a 5.8% yield with improving subscriber metrics and fiber growth opportunities. Pfizer is flagged as risky due to unsustainable dividend payouts exceeding free cash flow, high debt from the Seagen acquisition, and an upcoming patent cliff on blockbuster drugs.

09/18/2026, 4:30 PM • The Motley Fool

If a Recession Is Coming, History Says This 1 No-Brainer ETF Is the Smartest Buy Right Now

With bond market signals suggesting potential recession risks, the Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) is positioned as a defensive investment option. The ETF gained 0.6% in 2022 when the S&P 500 fell 18.2%, offering exposure to recession-resilient sectors like consumer staples and healthcare while avoiding volatile tech stocks. Its 4.82% dividend yield and low volatility make it attractive for risk-averse investors seeking portfolio protection.

09/18/2026, 8:06 AM • The Motley Fool

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

09/17/2026, 6:49 AM • GlobeNewswire

Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities

The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.

09/15/2026, 6:40 AM • GlobeNewswire

Why Pfizer Stock Was so Healthy in August

Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.

09/08/2026, 4:34 PM • The Motley Fool

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

While Pfizer offers a higher dividend yield of 6.1%, AbbVie is positioned as the superior long-term dividend stock. AbbVie has demonstrated stronger revenue growth (138% over a decade vs. Pfizer's 18%), is a Dividend King with 53 consecutive years of dividend increases, and has successfully navigated the loss of Humira exclusivity through home-grown replacements Skyrizi and Rinvoq. In contrast, Pfizer faces significant patent cliff exposure between 2026-2028 with $17-18 billion in annual revenue at risk from generic competition.

09/08/2026, 12:45 PM • The Motley Fool

Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm

Vaxcyte CEO Grant Pickering sold 6,289 shares (~$384,900) to cover tax withholding on vesting restricted stock units, retaining 447,000 direct shares. The clinical-stage biotech company, up 95% over the past year, is awaiting pivotal Phase 3 trial data for VAX-31 in Q4 2026. With $2.5 billion in cash but burning $284.3 million quarterly, the company's future hinges on successful trial results.

09/08/2026, 5:24 AM • The Motley Fool

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

Eli Lilly's GLP-1 weight-loss drugs (Mounjaro, Zepbound) currently drive nearly two-thirds of revenue, but face competition and patent expiration risks. The company is strategically acquiring smaller biotech firms across autoimmune, mental health, sleep disorders, and infectious disease spaces to diversify its pipeline and prepare for when GLP-1 drugs are no longer its primary revenue driver.

09/07/2026, 5:15 PM • The Motley Fool

AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider

The global AI in pharmaceutical market is projected to grow from USD 3.07 billion in 2025 to USD 48.43 billion by 2035, with a CAGR of 31.76%. The U.S. market is expected to reach USD 15.10 billion and Europe USD 12.60 billion by 2035. Growth is driven by generative AI, adaptive trials reducing patient enrollment by 40%, regulatory endorsement including FDA's qualification of AIM-NASH, and increased venture capital investment in AI-first drug discovery platforms.

09/07/2026, 8:30 AM • GlobeNewswire

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

09/07/2026, 6:52 AM • GlobeNewswire